JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AbbVie Inc

Slēgts

SektorsVeselības aprūpe

198.07 -0.35

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

198

Max

198.64

Galvenie mērījumi

By Trading Economics

Ienākumi

1.3B

1.3B

Pārdošana

2.1B

15B

P/E

Sektora vidējais

92.578

34.393

EPS

2.97

Dividenžu ienesīgums

3.31

Peļņas marža

9.66

Darbinieki

55,000

EBITDA

-4.3B

117M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+9.3% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.31%

2.54%

Nākamie ieņēmumi

2025. g. 29. okt.

Nākamais dividenžu datums

2025. g. 15. aug.

Nākamais Ex dividenžu datums

2025. g. 14. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

12B

348B

Iepriekšējā atvēršanas cena

198.42

Iepriekšējā slēgšanas cena

198.07

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

AbbVie Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. jūl. 12:46 UTC

Peļņas

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

2025. g. 30. jūn. 13:02 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

2025. g. 25. apr. 13:57 UTC

Peļņas

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

2025. g. 25. apr. 12:52 UTC

Peļņas

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

2025. g. 31. jūl. 12:08 UTC

Peļņas

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

2025. g. 31. jūl. 11:46 UTC

Peļņas

AbbVie Raises FY Outlook

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q Adj EPS $2.97 >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q EPS 52c >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q Rev $15.42B >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q International HUMIRA Rev $378M >ABBV

2025. g. 31. jūl. 11:44 UTC

Peļņas

AbbVie 2Q Net $938M >ABBV

2025. g. 30. jūn. 12:47 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

2025. g. 30. jūn. 12:33 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

2025. g. 30. jūn. 12:33 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

2025. g. 30. jūn. 12:32 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

2025. g. 30. jūn. 12:31 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

2025. g. 7. maijs 09:30 UTC

Top Ziņas

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

2025. g. 28. apr. 12:44 UTC

Peļņas

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025. g. 28. apr. 09:33 UTC

Peļņas

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025. g. 25. apr. 16:03 UTC

Peļņas

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025. g. 25. apr. 14:00 UTC

Top Ziņas
Peļņas

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

2025. g. 25. apr. 12:24 UTC

Top Ziņas
Peļņas

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

2025. g. 25. apr. 12:03 UTC

Top Ziņas
Peļņas

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

2025. g. 25. apr. 11:43 UTC

Peļņas

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

2025. g. 25. apr. 11:43 UTC

Peļņas

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Salīdzinājums

Cenas izmaiņa

AbbVie Inc Prognoze

Cenas mērķis

By TipRanks

9.3% augšup

Prognoze 12 mēnešiem

Vidējais 216.47 USD  9.3%

Augstākais 255 USD

Zemākais 170 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AbbVie Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

11

Pirkt

6

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

180.37 / 195.54Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.